13 May 2020 in Aesthetic Surgery Journal
Background: Blindness is a rare but catastrophic complication of facial hyaluronic acid (HA) injection. Although various means to rescue visual impairment have been employed, no consensus regarding effective treatment has yet been reached. We organized a multidisciplinary team to address this emergency situation by means of endovascular hyaluronidase application. Objectives: The aim of this study was to investigate the direct delivery of hyaluronidase to ophthalmic artery occlusion through endovascular cannulation to resolve HA-induced blindness. Methods: Four patients with visual impairments caused by HA filler embolization were subjected to sequential treatments. Through superselective angiography, a microcatheter was introduced along a guidewire from the femoral artery to the ophthalmic artery to directly deliver hyaluronidase to the HA embolism. The safety and efficiency of this treatment were systematically analyzed. Results: Selective cerebral angiography demonstrated that the endovascular application of hyaluronidase significantly alleviated occlusion in 3 patients. One patient showed slight visual improvement, whereas the other patients showed no improvement in their visual function during a follow-up period of more than 3 months. One patient suffered from cerebral infarction in the left middle cerebral artery during the intervention surgery. Moreover, 2 patients showed multiple lacunar cerebral infarctions after the operation, whereas none exhibited symptoms of hemiplegia during follow-up. Conclusions: Although the endovascular application of hyaluronidase could partially recanalize the occluded branches of the ophthalmic artery, it had limited effects on restoring vision. Considering the risks of vascular intervention surgery, this approach should be considered with caution. Level of Evidence: 5:
10 December 2022 in Aesthetic Surgery Journal
Background: Vision loss is a serious complication of hyaluronic acid (HA) filler injections, and long-term observations regarding the prognosis, particularly with angiography, are rare. Objectives: This study aimed to investigate the long-term prognosis and living status of patients with visual defects due to HA filler injections. Methods: Nine patients with vision loss caused by HA filler injections and receiving different treatments were included and followed up for 2 to 6 years after their accident. Follow-ups, including outpatient ophthalmologic examinations, were performed. Results: In the follow-up observation, all patients had reintegrated into society and work. The prognosis was similar for all hyaluronidase treatments, including retrobulbar injections and superselective ophthalmic artery thrombolysis. The facial appearance was not remarkably affected, and only 3 patients reported slight scarring. Ptosis disappeared in all the patients, and slight strabismus was found in 5 patients. However, vision improvement was very limited, even in the patients whose occluded retinal central artery received reperfusion. Conclusions: This long-term follow-up showed that the patients with vision loss caused by HA filler injections could reintegrate into society after treatment. Although the embolization of the retinal central artery led to reperfusion, vision was not restored, which further demonstrated the difficulty of recovering vision with the current treatment and the importance of prophylaxis. Autohydrolysis of HA by incorporating hyaluronidase-containing stimuli-responsive nanoparticles and a dual-pipe syringe are potential future approaches to address this catastrophic event.
15 June 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
29 December 2025 in ACS Polymers Au
Chronic inflammation is a hallmark of diabetic wounds, severely disrupting the physiological healing cascade. Modulating this inflammatory microenvironment while ensuring biocompatibility remains a major challenge in regenerative medicine. Herein, we report the development of a multifunctional dual-network injectable hydrogel, incorporating glycyrrhizic acid (GA) and acellular fat extracts (FE), designed to enhance diabetic wound repair. The hydrogel comprises two interpenetrating networks: A reversible, dynamic network formed via Zn2+-coordinated GA confers excellent injectability and conformability, allowing tight adherence to irregular wound topographies. A secondary, physically cross-linked network is introduced by ultraviolet (UV)-induced polymerization of methacrylated hyaluronic acid (HAMA), which significantly reinforces mechanical strength and structural stability. GA exhibits inherent immunomodulatory activity, promoting macrophage polarization from the pro-inflammatory M1 phenotype to the reparative M2 phenotype, thereby attenuating local inflammation. Concurrently, FE provides a rich reservoir of pro-angiogenic and regenerative bioactive factors that synergistically promote neovascularization and tissue remodeling. In vitro and in vivo evaluations confirmed that this composite hydrogel accelerates wound closure, reduces inflammatory cytokine expression, enhances angiogenesis, and promotes granulation tissue formation. Collectively, this injectable, immunomodulatory, and pro-regenerative hydrogel platform offers a promising therapeutic strategy for the effective management of recalcitrant diabetic wounds.